Lung Cancer Clinical Trials

Trials by mutation. Many non small cell lung cancer trials enroll only people whose tumor carries a specific change, such as KRAS G12C, EGFR, ALK, or c-Met overexpression. These test the next generation of targeted pills and antibody drug conjugates, often in people whose first targeted drug stopped working. Your tumor's genetic test report is the key to these studies.

Immunotherapy trials. Studies of new immune combinations, of immunotherapy given before surgery to shrink tumors, and of how to help people whose cancer does not respond to current checkpoint inhibitors.

Small cell lung cancer trials. A separate group, because this fast growing type behaves differently. New antibodies that link immune cells to cancer cells, and new chemotherapy combinations, are the focus, in a disease that saw almost no progress for 30 years until recently.

Surgery and radiation trials. Studies comparing removing a lung segment against focused radiation for small early tumors, testing proton therapy, and refining how much lung can be spared.

Screening and early detection. Only 1 in 5 eligible Americans is screened. Studies test blood based detection, better ways to reach eligible people, and screening for those who never smoked. These enroll people with no diagnosis.

Biomarker and observational studies. Liquid biopsies that track tumor DNA in blood, registries following people over time, and studies of why never smokers develop lung cancer. No treatment is given, and eligibility is often broad.

Lung cancer trials sort people by type, stage, and increasingly by mutation. The type: non small cell or small cell, and within non small cell, adenocarcinoma or squamous. The stage: early (I to III, often around surgery) or metastatic (IV). The tumor's genetic profile: many trials require a specific change like EGFR, ALK, KRAS G12C, or c-Met, or a certain level of PD-L1, the marker that predicts immunotherapy response. And treatment history: whether you have had immunotherapy, chemotherapy, or a targeted drug, and whether the cancer progressed on it. Smoking history matters for screening studies and some prevention research, but most treatment trials accept smokers and never smokers alike. Screening studies enroll people at high risk with no diagnosis, and biomarker studies often accept anyone with lung cancer. Eligibility always varies by study.

Smoking causes most cases, and the risk drops after quitting. But 10 to 20 percent of lung cancers occur in people who never smoked. Radon gas in homes is the second leading cause, followed by secondhand smoke, air pollution, asbestos and other workplace exposures, and family history. Some cancers arise from gene changes with no known trigger.

Nobody knows yet, and that is the honest answer. Vaping is too new for the decades of data that linked cigarettes to lung cancer. What is known: vape aerosol contains some of the same cancer causing chemicals as cigarette smoke, usually at lower levels, along with metals and flavor compounds whose long term effects are unstudied. Vaping is almost certainly less harmful than smoking, and almost certainly not harmless.

Non small cell lung cancer is staged I to IV by tumor size, lymph node involvement, and spread. Small cell lung cancer is usually described as limited stage (confined to one side of the chest) or extensive stage.

Stage I. A small tumor confined to the lung. Usually treated with surgery or, for people who cannot have surgery, focused radiation. Five year survival for localized disease is about 65 percent, but only 28 percent of lung cancers are found this early.

Stage II and III. Larger tumors or spread to lymph nodes in the chest. Treatment combines surgery, chemotherapy, radiation, and increasingly immunotherapy or targeted therapy given before or after surgery. This is where some of the most important recent trials have run.

Stage IV. Spread to the other lung, fluid around the lung, or distant organs such as brain, bone, or liver. About 43 percent of lung cancers are found at a late stage. Not curable today, but treatment depends heavily on mutation and PD-L1 testing, and for people with a targetable mutation or strong immunotherapy response, control for years is now common.

Study titles say "early stage," "resectable," "locally advanced," or "metastatic," and usually name the type and often a mutation. Your stage, your type, and your tumor's genetic test report tell you at a glance which studies fit.

Enrolling in a lung cancer study through our platform takes about 5 minutes. Here is how it works:

Identify your trial. Use the search bar or filters. Lung cancer study titles are specific: they name the type (non small cell or small cell), the stage, and very often a mutation or marker (KRAS G12C, EGFR, c-Met, PD-L1). Match those to your pathology and genetic test reports and most studies rule themselves in or out from the title.

Select your preferred location. Enter your city or state in the filter on the left. Drug trials involve regular infusions, scans, and blood work at a cancer center, so distance matters. Screening and biomarker studies are often closer to home.

Explore study details. Click "Learn More" for goals, procedures, and eligibility, including which mutations or PD-L1 level are required, which prior treatments are needed or excluded, and whether a fresh biopsy is part of screening.

Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your lung cancer type and stage, your tumor's genetic test results (mutations and PD-L1), and the list of treatments you have had. Those three answers decide eligibility for nearly every lung cancer study. If you have not had genetic testing yet, say so; it is worth asking your oncologist about, because it opens many studies.

Submit the application. A clinical trial coordinator reviews it and contacts you about whether you may qualify. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Your oncologist stays involved throughout.